Axsome Therapeutics, Inc. (AXSM)
Nasdaq · Healthcare · Biotechnology
$177.08−1.21%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $9.3B
- Forward P/E
- 37.5
- 52-week range
- $117.30 – $260.19
- 52-week change
- +51.09%
- EPS (trailing)
- −$3.74
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $639M (+65.55%)
- Net income
- −$183M
- Operating margin
- −26.1%
- Diluted EPS
- −$3.68
- Free cash flow
- −$93.9M
From the company’s annual report on SEC EDGAR.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Headquarters: New York, United States · 1,346 employees · axsome.com